[
    "<p><strong>Methods &amp; Materials</strong>:",
    "We will study the serum levels of</p><p>Interleukin 6 and serum zinc in TB patients, at Day</p><p>0, after one month, and after six months, </p><p><br></p><p>Study Design</p><p>  Study Type:</p><p> Interventional</p><p>   Estimated Enrollment:</p><p> 200 participants</p><p>   Allocation:</p><p> Randomized</p><p>   Intervention Model:</p><p>",
    "Parallel Assignment</p><p>   Masking:</p><p>",
    "Single (Participant)</p><p>Participant</p><p>   Primary Purpose:</p><p> Treatment</p><p>       Estimated Study Start Date:</p><p>",
    "November 2021</p><p>   Estimated Primary Completion Date:</p><p>",
    "February 2022</p><p>   Estimated Study Completion Date:</p><p>",
    "February 2022</p><p>  Primary outcome: conversion of positive pulmonary tuberculosis patients to negative after one month</p><p><br></p><p>Study design: </p><p>Interventional study randomized as 2 arms </p><p>Arm 1 100 pulmonary positive new diagnosed patients ",
    "Take national tuberculosis protocol adding to ",
    "Supplement zinc 50 mg 400 mg once daily </p><p>Arm 2 control group 100 patients only on tuberculosis national protocol&nbsp;</p><p><br></p><p>Inclusion criteria: </p><p>1-",
    "new diagnosed pulmonary positive t.b patients </p><p>2- age above 18 years </p><p>3- any patients with HIV and immuncromoised with t.b patients </p><p>4- patients with covid 19 and t.b </p><p>5- patients with drug t.b resistant </p><p>6- male or female </p><p>7-",
    "all races African or Asian or white </p><p>Exclusion\u2019s criteria </p><p>1- less than 18 years </p><p>2-",
    "pregnant female </p><p>3- on another ",
    "Supplement </p><p><br></p><p><br></p><p>&nbsp;</p><p><br></p><p><br></p><p><br></p><p><br></p><p><br></p><p><br></p><p><br></p><p><br></p><p><br></p><p><br></p>"
]